These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 12884153)

  • 21. How rebates, copayments, and administration costs affect the cost-effectiveness of osteoporosis therapies.
    Ferko NC; Borisova N; Airia P; Grima DT; Thompson MF
    Manag Care; 2012 Nov; 21(11):44-52. PubMed ID: 23236717
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacoeconomic analysis of osteoporosis treatment with risedronate.
    Brecht JG; Kruse HP; Felsenberg D; Möhrke W; Oestreich A; Huppertz E
    Int J Clin Pharmacol Res; 2003; 23(4):93-105. PubMed ID: 15224498
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Treatment of osteoporosis provided from the orthopaedic surgeon's standpoint].
    Sohen S
    Nihon Rinsho; 2003 Feb; 61(2):258-62. PubMed ID: 12638218
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risedronate: a new bisphosphonate for the treatment of osteoporosis.
    Kessenich CR
    Nurse Pract; 2000 Mar; 25(3):106-8. PubMed ID: 10750124
    [No Abstract]   [Full Text] [Related]  

  • 25. Changes in bone resorption markers among Japanese patients with postmenopausal osteoporosis treated with alendronate and risedronate.
    Takada J; Iba K; Imoto K; Yamashita T
    J Bone Miner Metab; 2007; 25(2):142-6. PubMed ID: 17323185
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies.
    Boonen S; Laan RF; Barton IP; Watts NB
    Osteoporos Int; 2005 Oct; 16(10):1291-8. PubMed ID: 15986101
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
    Iwamoto J; Takeda T; Sato Y
    Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Combination therapy of bisphosphonate and estrogen for osteoporosis].
    Ohta H
    Nihon Rinsho; 2004 Feb; 62 Suppl 2():470-4. PubMed ID: 15035173
    [No Abstract]   [Full Text] [Related]  

  • 29. Gender differences in osteoporosis treatment: a review of clinical research.
    Crandall C
    J Gend Specif Med; 2000; 3(8):42-6. PubMed ID: 11253267
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Channeling and adherence with alendronate and risedronate among chronic glucocorticoid users.
    Curtis JR; Westfall AO; Allison JJ; Freeman A; Saag KG
    Osteoporos Int; 2006; 17(8):1268-74. PubMed ID: 16724286
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evidence to inform decision makers in Thailand: a cost-effectiveness analysis of screening and treatment strategies for postmenopausal osteoporosis.
    Kingkaew P; Maleewong U; Ngarmukos C; Teerawattananon Y
    Value Health; 2012; 15(1 Suppl):S20-8. PubMed ID: 22265062
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risedronic acid. NE 58095, risedronate sodium, Actonel.
    Drugs R D; 1999 Mar; 1(3):218-20. PubMed ID: 10566029
    [No Abstract]   [Full Text] [Related]  

  • 33. [Bisphosphonate use and related pharmaceutical issues II].
    Veszelyné Kotan E; Mészáros Á
    Acta Pharm Hung; 2016; 86(1):23-34. PubMed ID: 27295874
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Are there differences in bisphosphonates? (interview by Dr. Beate Schumacher)].
    Adachi JD
    MMW Fortschr Med; 2004 Aug; 146(31-32):53. PubMed ID: 15529719
    [No Abstract]   [Full Text] [Related]  

  • 35. [Weeks of pain, vertebral body fractures during sleep, invalidism. Save your osteoporosis patients from this fate].
    Minne HW; Pollähne W; Pfeifer M; Begerow B; Hinz C
    MMW Fortschr Med; 2002 Oct; 144(44):41-4. PubMed ID: 12494598
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alendronate (Fosamax) and risedronate (Actonel) revisited.
    Med Lett Drugs Ther; 2005 Apr; 47(1207):33-5. PubMed ID: 15843782
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis.
    Bilezikian JP
    Am J Med; 2009 Feb; 122(2 Suppl):S14-21. PubMed ID: 19187808
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term tolerability of the bisphosphonates in postmenopausal osteoporosis: a comparative review.
    Kherani RB; Papaioannou A; Adachi JD
    Drug Saf; 2002; 25(11):781-90. PubMed ID: 12222989
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Bisphosphonates in the prevention of vertebral and non-vertebral fractures in postmenopausal women with osteoporosis].
    Curković B
    Reumatizam; 2003; 50(2):49-50. PubMed ID: 15098377
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study.
    Rosen CJ; Hochberg MC; Bonnick SL; McClung M; Miller P; Broy S; Kagan R; Chen E; Petruschke RA; Thompson DE; de Papp AE;
    J Bone Miner Res; 2005 Jan; 20(1):141-51. PubMed ID: 15619680
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.